Research ArticleArticle
2021 GRAPPA Trainee Symposium: A Summary of Oral and Poster Presentations
April W. Armstrong, Rasika M. Reddy, Keith Colaco, Pamela A. Diaz, Raminderjit Kaur, David Simon, Matteo Vecellio and M. Elaine Husni
The Journal of Rheumatology April 2022, jrheum.211318; DOI: https://doi.org/10.3899/jrheum.211318
April W. Armstrong
As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.
Rasika M. Reddy
As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.
Keith Colaco
As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.
Pamela A. Diaz
As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.
Raminderjit Kaur
As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.
David Simon
As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.
Matteo Vecellio
As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.
M. Elaine Husni
As part of the supplement series GRAPPA 2021, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. A.W. Armstrong, MD, MPH, Department of Dermatology, University of Southern California, Los Angeles, California, USA; R.M. Reddy, BA, Department of Dermatology, University of Southern California, Los Angeles, California, USA; K. Colaco, MSc, Women's College Research Institute, Women's College Hospital, Institute of Medical Science, Toronto, Ontario, Canada; P.A. Diaz, MD, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada; R. Kaur, PhD, Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA; D. Simon, MD, Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, and Universitatsklinikum Erlangen, Erlangen, Germany; M. Vecellio, PhD, Department of Rheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy, and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Center, Oxford, UK; M.E. Husni, MD, MPH, Department of Rheumatologic and Immunologic Disease, Cleveland Clinic, Cleveland, Ohio, USA. AWA has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, BMS, EPI, Incyte, Leo Pharma, UCB, Janssen, Eli Lilly, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed; MEH has served on the National Psoriasis Foundation Board of Directors and as a research investigator and/or scientific advisor to AbbVie, Amgen, Novartis, Eli Lilly, Pfizer, UCB, and Janssen. The remaining authors declare no conflicts of interest. We have obtained ethical approval and informed consent if and when applicable. Address correspondence to Dr. A.W. Armstrong, University of Southern California, 1975 Zonal Avenue, KAM, MC 9034, Los Angeles, CA 90089, USA. Email: armstrongpublication@gmail.com. Accepted for publication December 7, 2021.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
2021 GRAPPA Trainee Symposium: A Summary of Oral and Poster Presentations
April W. Armstrong, Rasika M. Reddy, Keith Colaco, Pamela A. Diaz, Raminderjit Kaur, David Simon, Matteo Vecellio, M. Elaine Husni
The Journal of Rheumatology Apr 2022, jrheum.211318; DOI: 10.3899/jrheum.211318